Two studies led by Roswell park Comprehensive Cancer Center of Buffalo, New York has revealed that intake of aspirin in low doses may improve health condition of patients battling cancer of neck, head and also lung cancer. The first study reviewed data of around 460 patients that were suffering from squamous cell carcinoma (HNSCC) related to head/neck and early stage non-small cell lung cancer (NSCLC). The study revealed that it increased give year survival rate of patients taking non-steroidal anti-inflammatory medicine like aspirin with standard radiation or chemotherapy by nearly 8 percent. Another study by the same group was on a group of 164 patients that underwent high level of radiation for NSCLC.
When these patients took low dose aspirin it helped around 57 percent of them to reach the two year survival mark in comparison to remaining 48 percent. Both studies were undertaken by Dr. Anurag Singh, a professor of oncology at Roswell and his team. Details of both studies were presented early this month during annual meetings of American Society for Therapeutic Radiation Oncology at Chicago. Co-author of first study Dr. Austin Iovoli serving a residency at Roswell stated that the team was especially interested in witnessing how patients were able to live for longer periods even though the aspirin did not have any detrimental impact on the cancer medication.
According to Dr. Gregory Hermann, another resident doctor at Roswell who was part of the second study, these studies shows the beneficial use of anti-inflammatory drugs by cancer patients. In a cancer center based news release Dr. Gregory stated that clinical trials will have to be done to make official recommendations to patients. But he said that patients should talk to their personal physicians about risks and benefits of aspirin use based on their medical condition for cancer treatment.